AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 212 min read$ABT

Abbott Plans to Separate Nutrition Business Into Publicly Traded Company by End of 2027

Abbott Laboratories (ABT) plans to spin off its Nutrition division, generating $8.5B in annual revenue, into a separate publicly traded company by the end of 2027. The move, subject to approvals, will allow Abbott to focus on medical devices, diagnostics, and pharmaceuticals, with the new company led by Daniel Salvadori. Existing shareholders will receive shares in both entities, and the transaction is not expected to affect Abbott's 2026 or 2027 financial guidance.

Original reporting
finance.yahoo.com
Published Oct 21, 2026, 1:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 2:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Abbott Plans to Separate Nutrition Business Into Publicly Traded Company by End of 2027 — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ABTNeutralHigh
01

Why it matters

The announced spin‑off separates consumer nutrition from Abbott’s core medical businesses, creating a new listed entity and altering the company’s revenue mix.

02

Market read

First‑report corporate restructuring of a large‑cap healthcare firm, likely to generate short‑term trading activity.

03

What to watch

Potential tax‑free distribution and dividend continuity may mitigate downside risk.

Relevance 7/10Novelty 9/10Timing: immediate upon announcement

Background

Abbott Laboratories (ABT) is a diversified healthcare company with medical devices, diagnostics, pharmaceuticals, and a nutrition segment.

Company-level read

Ticker impact

$ABTNeutralHigh confidence
Context

Abbott announced a spin‑off of its Nutrition division into a new publicly traded company.

Expected impact

likely pressure as the market prices in the upcoming separation and potential dividend adjustments

Evidence & confidence

Spin‑offs often cause investors to reassess the parent’s earnings profile and dividend outlook, leading to short‑term volatility.

Market effects

Sector

Healthcare sector may see re‑rating of consumer‑health versus medical‑devices segments.

Regional

U.S. large‑cap healthcare index could be modestly affected by Abbott’s move.

Global

Limited to investors tracking major U.S. healthcare stocks.

Counterpoint

What could challenge this read

The spin‑off could unlock value if the nutrition business is undervalued within Abbott.

Key entities

  • company
    Abbott Laboratories

    Parent healthcare company planning the spin‑off.

  • person
    Daniel Salvadori

    Appointed CEO of the future nutrition company.

Read at source← All news

StoryAbbott to spin off Nutrition unit into independent public company by end‑2027

Also covered by

6 outlets

Related articles

OCT 21
$ABTHigh

Abbott Laboratories (ABT) Revises Growth Outlook, Plans Nutritio

Abbott Laboratories (ABT) lowered its full-year growth forecast and announced a spin-off of its nutrition business, causing a premarket decline. Despite this, the company reported Q3 revenues of $13.0 billion, a 14.5% YoY increase. ABT offers a 2.56% dividend yield, a payout ratio of 80%, and a GF Value of $135.69, suggesting modest undervaluation. Insider activity shows net selling, while 23 premium gurus hold ABT shares.

gurufocus.com2 min
OCT 21
$ABTMed

Abbott Stock Falls 4% on Similac Spinoff: It’s Shedding Its Slowest Business, but Who Keeps the Lawsuits?

Abbott Laboratories (ABT) shares dropped 4% after announcing plans to spin off its Nutrition business, including Similac, by 2027. The unit generates $8.5B annually but has shown minimal growth. The move leaves Abbott with a medical device and diagnostics business, with $42B in annual sales. The company expects to maintain its 2026 guidance and current dividend payouts. Daniel Salvadori will lead the new nutrition company.

finance.yahoo.com2 min
OCT 21
$ABTHighAI 8/10

Abbott Laboratories Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

Abbott Laboratories reported Q3 2026 sales of $13.01B (up from $11.37B YoY) and net income of $920M (down from $1.64B YoY). Nine-month sales reached $36.77B (up from $32.87B YoY), with net income of $2.93B (down from $4.75B YoY). The company's products include vascular devices, diagnostic systems, nutrition products, and medicines, with sales distributed globally.

marketscreener.com2 min
OCT 21
$ABTHighAI 8/10

Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company

ABBOTT LABORATORIES (ABT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company • Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies • The new Nutrition company will be a gl

SEC EDGAR 8-K3 min
OCT 21
$ABTMed

Abbott to Carve Out Nutrition Business Into Independent Company -- 2nd Update

Abbott Laboratories plans to separate its nutrition business, with $8.5B in annual sales, into an independent company by 2027. The move aims to focus on higher-growth areas. Shares fell 4% premarket. Q3 sales rose 14% to $13.01B, but profit declined due to higher costs. Abbott faces ongoing litigation over its baby-formula facility and has agreed to multimillion-dollar settlements.

marketscreener.com2 min